Maxim Logo new.png
M-Vest and Maxim Group LLC to Host a panel discussion on Innovations in ALS: Exploring New Treatments In Development on Tuesday, June 28th at 11 A.M. EDT
June 27, 2022 09:30 ET | Maxim Group LLC
NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- Maxim Group LLC, a full-service investment banking, securities and wealth management firm, and M-Vest, a digital community built for issuers, investors,...
clene-logo@2x.png
Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
June 27, 2022 07:00 ET | Clene Inc.
SALT LAKE CITY, June 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
PasitheaLogo.png
Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC
June 22, 2022 08:00 ET | Pasithea
- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core...
Ferrer Brings ALSton the Dragon to Life to Raise Awareness of ALS
June 21, 2022 04:00 ET | Ferrer
BARCELONA, Spain, June 21, 2022 (GLOBE NEWSWIRE) -- On Global Amyotrophic Lateral Sclerosis / Motor Neuron Disease (ALS/MND) Awareness Day on June 21, the Phantasticals campaign, run by Ferrer, the...
eledon-logo-1230.png
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2022 16:05 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
June 09, 2022 08:00 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Biogen_Logo_Standard-rgb_R.jpg
New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS
June 03, 2022 05:20 ET | Biogen Inc.
12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of lifeTofersen also led to robust and sustained...
eledon-logo-1230.png
Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2022 16:05 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis
May 31, 2022 06:00 ET | Eledon Pharmaceuticals, Inc.
Tegoprubart was well-tolerated, with no drug-related serious adverse eventsDose dependent target engagement was demonstrated, and ALS associated pro-inflammatory biomarkers were both observed and...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
May 18, 2022 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership...